Caroline J. Rieser

Caroline J. Rieser

Auto-generated profile, based on publicly available information

Caroline J. Rieser

Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2021 in Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
RHRichard Hoehn
Richard Hoehn
CRCaroline J. Rieser
Caroline J. Rieser
HPHeather Phelos
Heather Phelos
LSLindsay M. Sabik
Lindsay M. Sabik
INIbrahim Nassour
Ibrahim Nassour
STSamer T. Tohme
Samer T. Tohme
Background: Medicaid expansion under the Affordable Care Act has improved access to screening and treatment for certain cancers. It is unclear how this policy has affected the diagnosis and management of pancreatic cancer.Methods: Using a quasi‐experimental difference‐in‐differences (DID) approach, we analyzed Medicaid and uninsured patients in the National Cancer Data Base during two time periods: pre‐expansion (2011–2012) and postexpansion (2015–2016). We investigated changes in cancer staging, treatment decisions, and surgical outcomes.Results: In this national cohort, pancreatic cancer patients in expansion states had increased Medicaid coverage relative to those in nonexpansion states (DID = 17.49, p < 0.01). Medicaid expansion also led to an increase in early‐stage diagnoses (Stage I/II, DID = 4.71, p = 0.03), higher comorbidity scores among surgical patients (Charlson/Deyo score 0: DID = −13.69, p = 0.02), a trend toward more neoadjuvant radiation (DID = 6.15, p = 0.06), and more positive margins (DID = 11.69, p = 0.02). There were no differences in rates of surgery, postoperative outcomes, or overall survival.Conclusion: Medicaid expansion was associated with improved insurance coverage and earlier stage diagnoses for Medicaid and uninsured pancreatic cancer patients, but similar surgical outcomes and overall survival. These findings highlight both the benefits of Medicaid expansion and the potential limitations of policy change to improve outcomes for such an aggressive malignancy.

9 March 2021 in Annals of Surgical Oncology
Verified
Journal Article
Open access
PDF file
CRCaroline J. Rieser
Caroline J. Rieser
RHRichard S. Hoehn
Richard S. Hoehn
MZMazen Zenati
Mazen Zenati
LHLauren B. Hall
Lauren B. Hall
EKEliza Kang
Eliza Kang
MCM. Haroon A. Choudry
M. Haroon A. Choudry
Background: Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion (CRS HIPEC) can offer significant survival advantage for select patients with colorectal peritoneal metastases (CRPM). Low socioeconomic status (SES) is implicated in disparities in access to care. We analyze the impact of SES on postoperative outcomes and survival at a high-volume tertiary CRS HIPEC center. Patients and Methods: We conducted a retrospective cohort study examining patients who underwent CRS HIPEC for CRPM from 2000 to 2018. Patients were grouped according to SES. Baseline characteristics, perioperative outcomes, and survival were examined between groups. Results: A total of 226 patients were analyzed, 107 (47%) low-SES and 119 (53%) high-SES patients. High-SES patients were younger (52 vs. 58 years, p = 0.01) and more likely to be White (95.0% vs. 91.6%, p = 0.06) and privately insured (83% vs. 57%, p < 0.001). They traveled significantly further for treatment and had lower burden of comorbidities and frailty (p = 0.01). Low-SES patients more often presented with synchronous peritoneal metastases (48% vs. 35%, p = 0.05). Following CRS HIPEC, low-SES patients had longer length of stay and higher burden of postoperative complications, 90-day readmission, and 30-day mortality. Median overall survival following CRS HIPEC was worse for low-SES patients (17.8 vs. 32.4 months, p = 0.02). This disparity persisted on multivariate survival analysis (low SES: HR = 1.46, p = 0.03). Conclusions: Despite improving therapies for CRPM, low-SES patients remain at a significant disadvantage. Even patients who overcome barriers to care experience worse short- and long-term outcomes. Improving access and addressing these disparities is crucial to ensure equitable outcomes and improve patient care.

8 April 2021 in Journal of Surgical Research
Verified
Journal Article
Closed access
KHKatherine A. Hrebinko
Katherine A. Hrebinko
CRCaroline Rieser
Caroline Rieser
INIbrahim Nassour
Ibrahim Nassour
STSamer Tohme
Samer Tohme
LSLindsay M. Sabik
Lindsay M. Sabik
RHRichard Hoehn
Richard Hoehn

1 March 2021 in Journal of Trauma and Acute Care Surgery
Verified
Journal Article
Closed access
CRCaroline J. Rieser
Caroline J. Rieser
EDEsmaeel R. Dadashzadeh
Esmaeel R. Dadashzadeh
RHRobert M. Handzel
Robert M. Handzel
KCKadie J. Clancy
Kadie J. Clancy
CKChristof T. Kaltenmeier
Christof T. Kaltenmeier
MRMatthew R. Md Rosengart
Matthew R. Md Rosengart
BACKGROUND: The significance of pneumatosis intestinalis (PI) remains challenging. While certain clinical scenarios are predictive of transmural ischemia, risk models to assess the presence of pathologic PI are needed. The aim of this study was to determine what patient factors at the time of radiographic diagnosis of PI predict the risk for pathologic PI. METHODS: We conducted a retrospective cohort study examining patients with PI from 2010 to 2016 at a multicenter hospital network. Multivariate logistic regression was used to develop a predictive model for pathologic PI in a derivation cohort. Using regression-coefficient–based methods, the final multivariate model was converted into a five-factor–based score. Calibration and discrimination of the score were then assessed in a validation cohort. RESULTS: Of 305 patients analyzed, 102 (33.4%) had pathologic PI. We identified five factors associated with pathologic PI at the time of radiographic diagnosis: small bowel PI, age 70 years or older, heart rate 110 bpm or greater, lactate of 2 mmol/L or greater, and neutrophil-lymphocyte ratio 10 or greater. Using this model, patients in the validation cohort were assigned risk scores ranging from 0 to 11. Low-risk patients were categorized when scores are 0 to 4; intermediate, score of 5 to 6; high, score of 7 to 8; and very high risk, 9+. In the validation cohort, very high-risk patients (n = 17; 18.1%) had predicted rates of pathologic pneumatosis of 88.9% and an observed rate of 82.4%. In contrast, patients labeled as low risk (n = 37; 39.4%) had expected rates of pathologic pneumatosis of 1.3% and an observed rate of 0%. The model showed excellent discrimination (area under the curve, 0.90) and good calibration (Hosmer-Lemeshow goodness-of-fit, p = 0.37). CONCLUSION: Our score accurately stratifies patient risk of pathologic pneumatosis. This score has the potential to target high-risk individuals for expedient operation and spare low-risk individuals invasive interventions. LEVEL OF EVIDENCE: Prognostic Study, Level III.

5 July 2021 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
CRCaroline J. Rieser
Caroline J. Rieser
HJHeather Jones
Heather Jones
LHLauren B. Hall
Lauren B. Hall
EKEliza Kang
Eliza Kang
SAShannon Altpeter
Shannon Altpeter
DBDavid L. Bartlett
David L. Bartlett

10 November 2023 in HPB
Verified
Journal Article
Closed access
MWMichael M. Wach
Michael M. Wach
LWLaura A. Washburn
Laura A. Washburn
JAJurgis Alvikas
Jurgis Alvikas
LQLinda Qu
Linda Qu
MZMichelle Zhang
Michelle Zhang
STSamer Tohme
Samer Tohme